Verano Holdings (VRNO) Asset Writedowns and Impairment (2021 - 2025)
Verano Holdings' (VRNO) quarterly Asset Writedowns and Impairment came in at $177.4 million in Q4 2025, down 45.85% year-on-year from $327.7 million in Q4 2024, and up 3185.93% on a QoQ basis from $5.4 million in Q3 2025.
Verano Holdings (VRNO) Asset Writedowns and Impairment (2021 - 2025) Analysis & Trends
Verano Holdings (VRNO) has 5 years of Asset Writedowns and Impairment data on file, last reported at $177.4 million in Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment fell 45.85% year-over-year to $177.4 million in Q4 2025; TTM through Dec 2025 was $511.0 million, a 55.87% increase from a year earlier, with the FY2025 full-year figure at $183.3 million, down 44.07% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $177.4 million, up from $5.4 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for VRNO reached as high as $327.7 million in Q4 2024 and fell as low as -$2.2 million in Q4 2022.
- Historically, Asset Writedowns and Impairment has averaged $43.1 million across 5 years, with a median of $510500.0 in 2023.
- Across the five-year window, Asset Writedowns and Impairment sank 2468.24% in 2022 and retreated 12.02% in 2023, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at -$85000.0 in 2021, then slumped by 2468.24% to -$2.2 million in 2022, then soared by 401.01% to $6.6 million in 2023, then soared by 4887.05% to $327.7 million in 2024, then sank by 45.85% to $177.4 million in 2025.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $177.4 million in Q4 2025, $5.4 million in Q3 2025, and $428000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Verano Holdings | 1.99 Bn | 1.91 Bn | 98.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 177.44 Mn |
| Dec 31, 2025 | 177.44 Mn |
| Sep 30, 2025 | 5.40 Mn |
| Sep 30, 2025 | 5.40 Mn |
| Jun 30, 2025 | 428,000.00 |
| Jun 30, 2025 | 428,000.00 |
| Dec 31, 2024 | 327.70 Mn |
| Dec 31, 2024 | 327.70 Mn |
| Mar 31, 2024 | 112,000.00 |
| Mar 31, 2024 | 112,000.00 |
| Sep 30, 2023 | 6.57 Mn |
| Sep 30, 2023 | 6.57 Mn |
| Mar 31, 2023 | 593,000.00 |
| Mar 31, 2023 | 593,000.00 |
| Dec 31, 2022 | -2.18 Mn |
| Dec 31, 2022 | -2.18 Mn |
| Jun 30, 2022 | 342,000.00 |
| Jun 30, 2022 | 342,000.00 |
| Mar 31, 2022 | 674,000.00 |
| Mar 31, 2022 | 674,000.00 |